Please Join us for an Educational Dessert Symposium...

Novel Treatment Targets in CYSTIC FIBROSIS
The ΔF508 CFTR Mutation & Beyond

Friday, October 9, 2015 • 7:30 PM* – 9:30 PM
DESSERT AND REFRESHMENTS PROVIDED

Sheraton Phoenix Downtown Hotel
340 North 3rd Street
Phoenix CDE Ballroom
Phoenix, Arizona

*On-site registration from 7:30 PM – 8:00 PM

This activity is supported through an educational grant from Nivalis Therapeutics

This activity is jointly provided by Medical Education Resources and Delaware Media Group
SYMPOSIUM FACULTY

Chairperson
Scott H. Donaldson, MD
Associate Professor
Department of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Adult Cystic Fibrosis Program
University of North Carolina
Chapel Hill, North Carolina

Faculty Presenters
John P. Clancy, MD
Gunnar Esiasion/Cincinnati Bell Chair
Research Director, Division of Pulmonary Medicine
Cincinnati Children’s Hospital Medical Center
Professor, Department of Pediatrics
University of Cincinnati College of Medicine
Cincinnati, Ohio

Ronald C. Rubenstein, MD, PhD
Associate Professor of Pediatrics
Perelman School of Medicine at the University of Pennsylvania
Richard B. Johnston, Jr. Endowed Chair in Pediatrics
Director, Cystic Fibrosis Center
The Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Faculty disclosure will be included in the program syllabus.

PRE-REGISTER ONLINE AT: delmedgroup.com
OR
Register in person from 7:30 PM to 8:00 PM at:
Sheraton Phoenix Downtown Hotel
Phoenix CDE Ballroom

While every effort will be made to accommodate each attendee, due to limited space, there is no guarantee of admittance into this program.
Novel Treatment Targets in CF: The ΔF508 CFTR Mutation & Beyond will examine the pathological mechanisms of the most common CFTR mutation, ΔF508, and how its associated defects disrupt protein assembly, maturation, degradation, and chloride channel activity. The program will also cover the latest research on novel mechanism-based modulators currently being investigated in CF, including GSNOR inhibitors, RNA repair modulators, and ENaC inhibitors, and will discuss the unique ways in which these compounds work to restore chloride channel activity. In addition, the program will explore personalized medicine approaches that utilize multimodal and theratype treatment methods to refine and prioritize therapy options.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of pediatric and adult pulmonologists, pulmonary intensivists, and internists involved in the care of patients with CF.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

1. Review defects associated with the ΔF508 CFTR mutation and how they alter CFTR protein assembly, maturation, degradation, and chloride channel activity.

2. Describe novel mechanism-based treatment modalities for CF, including GSNOR inhibitors, ENaC inhibitors, and RNA repair modulators.

3. Describe approaches to match patients to therapies based on CFTR mutation responsiveness and model system performance.
AGENDA

7:30 PM – 8:00 PM
On-site Registration

8:00 PM – 8:15 PM
Dessert & Introductions

8:15 PM – 8:30 PM
Ronald C. Rubenstein, MD, PhD
Structure and Regulation of CFTR & Mutation Behavior

8:30 PM – 8:55 PM
Scott H. Donaldson, MD
Novel Mechanism-Based Treatment Modalities for CF

8:55 PM – 9:15 PM
John P. Clancy, MD
Multimodal Treatment Approaches & Personalized Medicine

9:15 PM – 9:30 PM
Interactive Q & A

Novel Treatment Targets in
CYSTIC FIBROSIS
The ΔF508 CFTR Mutation & Beyond

Friday, October 9, 2015 • 7:30 PM* – 9:30 PM

DESSERT AND REFRESHMENTS PROVIDED

Sheraton Phoenix Downtown Hotel
340 North 3rd Street
Phoenix CDE Ballroom
Phoenix, Arizona

*On-site registration from 7:30 PM – 8:00 PM
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Delaware Media Group. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

There is no fee for this educational activity.
Novel Treatment Targets in
CYSTIC FIBROSIS
The ΔF508 CFTR Mutation & Beyond

PRE-REGISTER ONLINE AT: delmedgroup.com
OR
Register in person from 7:30 PM to 8:00 PM at:
Sheraton Phoenix Downtown Hotel
Phoenix CDE Ballroom

While every effort will be made to accommodate each attendee, due to limited space, there is no guarantee of admittance into this program.

This activity is supported through an educational grant from Nivalis Therapeutics

This activity is jointly provided by Medical Education Resources and Delaware Media Group